The activity-based cost of drug-susceptibility test of Mycobacterium tuberculosis through Kit SIRE Nitratase® plastlabor.

Simple item page
dc.contributor.authorAlmeida, Isabela Neves de
dc.contributor.authorSilva, Suely Conceição Alves da
dc.contributor.authorOliveira Junior, Haliton Alves de
dc.contributor.authorFigueredo, Lida Jouca de Assis
dc.contributor.authorSoares, Valéria Martins
dc.contributor.authorCarvalho, Wânia da Silva
dc.contributor.authorKritski, Afrânio
dc.contributor.authorFiori, Maria Cláudia da Silva Vater da Costa
dc.contributor.authorMiranda, Silvana Spíndola de
dc.date.accessioned2023-01-16T21:28:10Z
dc.date.available2023-01-16T21:28:10Z
dc.date.issued2020pt_BR
dc.description.abstractBackground: Drug‐resistant tuberculosis (TB) is an ongoing health threat, and the greatest challenge to adequate control of TB in many countries lies in the lack of proper laboratory drug‐susceptibility test. The aim of this study was to evaluate the activity‐based costs (ABC) of Kit SIRE Nitratase® (Kit SIRE) and compare its values with the conventional drug‐susceptibility test. Methods: The ABC was calculated for three different approaches: Kit SIRE (clinical samples and cultures), proportion methods in Lowenstein Jensen (PM‐LJ), and the BactecTM MGITTM 960 system based on Mycobacterial Research Laboratory’s routine. Results: The ABC of Kit SIRE from cultures was US$ 148.54, while from clinical samples was US$ 136.12. In the case of conventional tests, the ABC of BactecTM MGITTM 960 was US$ 227.63 and of the PM‐LJ was US$ 132.64. The Kit SIRE has a lower ABC when clinical samples are used instead of cultures. Compared to conventional tests, the ABC is similar to the PM‐LJ and lower the BactecTM MGITTM 960. Conclusion: The Kit SIRE should be used as a screening method in clinical specimens and in culture for laboratories that do not have BactecTM MGITTM 960. Therefore, it can be incorporated into the routine of laboratories in countries with low resources and a high burden of TB and drug‐resistant TB.pt_BR
dc.identifier.citationALMEIDA, I. N. de. et al. The activity-based cost of drug-susceptibility test of Mycobacterium tuberculosis through Kit SIRE Nitratase® plastlabor. International Journal of Mycobateriology, v. 9, p. 24-28, 2020. Disponível em: <https://www.ijmyco.org/article.asp?issn=2212-5531;year=2020;volume=9;issue=1;spage=24;epage=28;aulast=de>. Acesso em: 11 out. 2022.pt_BR
dc.identifier.doihttps://doi.org/10.4103/ijmy.ijmy_8_20pt_BR
dc.identifier.issn2212 - 554X
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/15950
dc.identifier.uri2https://www.ijmyco.org/article.asp?issn=2212-5531;year=2020;volume=9;issue=1;spage=24;epage=28;aulast=dept_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectMultidrug‐resistant tuberculosispt_BR
dc.subjectNitrate reductasept_BR
dc.subjectTechnologypt_BR
dc.titleThe activity-based cost of drug-susceptibility test of Mycobacterium tuberculosis through Kit SIRE Nitratase® plastlabor.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_ActivityBasedCost.pdf
Size:
525.47 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos